Type 2 Diabetes Mellitus — Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride
Citation(s)
A Multi-center, Randomized, Double-blind Placebo Controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With Vildagliptin 50 mg Bid as add-on Therapy to Metformin Plus Glimepiride in Patients With Type 2 Diabetes